Only bull market is in intervention

Eleanor Creagh

Australian Market Strategist, Saxo

Summary:  Asia equities trade subdued into the weekend after a broadly flat lead from Wall Street and with US and European futures remaining under pressure and in the red most of the session. Nikkei -0.70%, KOSPI -0.89%, Hang Seng -0.60%, ASX200 +0.63% at the time of writing.


Risk looks set to continue to roll over in tandem with the real economy outlook, as collapsing economic data, failed drug trials and tech concerns fuel a more cautious mood. For the AUD that as a global risk proxy has bounced hard in recent weeks looking through the collapsing data towards the recovery, as risk rolls over the currency is primed for disappointment. Although FX moves in today’s Asia trading session are muted. 

Gilead’s coronavirus drug Remdesivir has failed its first trial in China according to the Financial Times, contrary to documents released last week that sent US stocks surging higher on Friday. Overnight US equities pushed higher, with little regard for the addition 4.4mn jobless claims, and cratering PMIs in the US, EZ, Germany, France and the UK, something we touched on yesterday. But when news hit that the previously heralded antiviral was less cure more failure, those gains promptly reversed. The S&P 500 staged another reversal on the 50-day moving average and failed to close above, playing into to the theory that recent moves remain a bear market bounce driven by technicals as opposed to anything more meaningful. Without a vaccine or viable antiviral treatment imminent, the optimistic hopes for a V shaped snapback in activity and profits is fading fast. The re-opening process therefore being a phased transition and bounce back in activity being a slow return to normal levels. With the scale of job losses globally mounting, second order implications take centre stage and alongside a longer lasting drag on activity, the V-shaped recovery in employment can be ruled out. Job insecurity, lost savings and personal safety concerns dampen consumption as consumers choose to save more and spend less, preventing a one-quarter and done impact. Alongside plunging economic indicators it is likely that the consensus for earnings and equity fundamentals remains too optimistic at these levels, despite “QE Infinity” and fed intervention. Longer-term mounting debt levels, de-globalisation and receding international cooperation dull potential growth further.

Google to Slash Marketing Budgets by Up to Half in a bid to reduce expenses, according to internal memos seen by CNBC. The stock is down in after hours, but the read through to other tech stocks is equally as important. As we have previously noted, for investors hiding in tech stocks, some revenues may be far more cyclical than consensus expects. Digital advertising budgets are being slashed across the board and Facebook, Alphabet, Twitter, Snapchat will not be immune. Decelerating advertising growth and digital ad spending is bad news given that Google and Facebook’s revenues are heavily tied to ad spending. Google in particular has more than a third of advertising revenues tied to sectors which have been hit hard by the impact of COVID-19 - Travel, Automotive and Financials. For an indicator of how much spending is actually being cut Barry Diller, chairman Expedia, speaking with CNBC earlier this month said that they typically spend $5bn on ads, but probably “won’t spend $1bn this year”.

Is the oil bailout pending? Treasury Secretary Steve Mnuchin said he’s considering creating a government lending program for U.S. oil companies. Sounds like it! The problem here, over supply has been a key component of the fallout in the oil market alongside demand destruction.If the market cannot be allowed to force production cuts due to bailout intervention then the problem of over supply remains, against a fundamental backdrop of demand that remains incredibly subdued. The only bull market is in intervention! 

EUCO meeting leaves many questioning what is Europe if not for solidarity in times of crisis like the present. The positive - the failure to reach a conclusion on the long-term stimulus plan, is favourable to a bad plan. All or nothing? For more, Christopher Dembik has the analysis.

Disclaimer

The Saxo Bank Group entities each provide execution-only service and access to Analysis permitting a person to view and/or use content available on or via the website. This content is not intended to and does not change or expand on the execution-only service. Such access and use are at all times subject to (i) The Terms of Use; (ii) Full Disclaimer; (iii) The Risk Warning; (iv) the Rules of Engagement and (v) Notices applying to Saxo News & Research and/or its content in addition (where relevant) to the terms governing the use of hyperlinks on the website of a member of the Saxo Bank Group by which access to Saxo News & Research is gained. Such content is therefore provided as no more than information. In particular no advice is intended to be provided or to be relied on as provided nor endorsed by any Saxo Bank Group entity; nor is it to be construed as solicitation or an incentive provided to subscribe for or sell or purchase any financial instrument. All trading or investments you make must be pursuant to your own unprompted and informed self-directed decision. As such no Saxo Bank Group entity will have or be liable for any losses that you may sustain as a result of any investment decision made in reliance on information which is available on Saxo News & Research or as a result of the use of the Saxo News & Research. Orders given and trades effected are deemed intended to be given or effected for the account of the customer with the Saxo Bank Group entity operating in the jurisdiction in which the customer resides and/or with whom the customer opened and maintains his/her trading account. Saxo News & Research does not contain (and should not be construed as containing) financial, investment, tax or trading advice or advice of any sort offered, recommended or endorsed by Saxo Bank Group and should not be construed as a record of our trading prices, or as an offer, incentive or solicitation for the subscription, sale or purchase in any financial instrument. To the extent that any content is construed as investment research, you must note and accept that the content was not intended to and has not been prepared in accordance with legal requirements designed to promote the independence of investment research and as such, would be considered as a marketing communication under relevant laws.

Please read our disclaimers:
- Notification on Non-Independent Investment Research (https://www.home.saxo/legal/niird/notification)
- Full disclaimer (https://www.home.saxo/en-gb/legal/disclaimer/saxo-disclaimer)

Trade Responsibly
All trading carries risk. To help you understand the risks involved we have put together a series of Key Information Documents (KIDs) highlighting the risks and rewards related to each product. Read more
Additional Key Information Documents are available in our trading platform.

Saxo Markets is a registered Trading Name of Saxo Capital Markets Ltd (‘SCML’). SCML is authorised and regulated by the Financial Conduct Authority, Firm Reference Number 551422. Registered address: 26th Floor, 40 Bank Street, Canary Wharf, London E14 5DA. Company number 7413871.

This website, including the information and materials contained in it, are not directed at, or intended for distribution to or use by, any person or entity who is a citizen or resident of or located in the United States, Belgium or any other jurisdiction where such distribution, publication, availability or use would be contrary to applicable law or regulation.

It is important that you understand that with investments, your capital is at risk. Past performance is not a guide to future performance. It is your responsibility to ensure that you make an informed decision about whether or not to invest with us. If you are still unsure if investing is right for you, please seek independent advice. Saxo Markets assumes no liability for any loss sustained from trading in accordance with a recommendation.

Apple, iPad and iPhone are trademarks of Apple Inc., registered in the U.S. and other countries. App Store is a service mark of Apple Inc. Android is a trademark of Google Inc.